title: Hyperaluminaemia in critically ill patients: role of antacid therapy and impaired renal function.
abstract: A significant rise in serum concentrations of aluminum was demonstrated in 23 patients prophylactically treated with the antacid magaldrate, whereas no increase in serum aluminium was observed in another 26 critically ill patients, in whom the use of antacids was avoided. In parallel, urinary excretion rates of aluminum rose to values close to maximum 72 h after antacid therapy had been started. Hyperaluminaemia was most marked in patients with acute renal failure undergoing continuous haemofiltration, but a significant increment in serum aluminium was also noted in patients with impaired renal function in the predialytic state. In the latter group and in patients with normal renal function there was a significant negative correlation between urinary excretion rates of aluminium and creatinine clearance after 48 h of treatment suggesting an enhancement of gastrointestinal absorption of aluminium in the presence of chronic renal failure. Maximum serum concentrations of aluminium did attain critical values in some patients with acute renal failure, but no overt signs of aluminium toxicity were noted. However, in light of both, possible subtle toxicity and enhanced absorption of aluminium in critically ill patients with renal failure, the prophylactic use of antacids in this setting should be re-evaluated cautiously.
authors.affiliation: Department of Internal Medicine II, R.W.T.H., Aachen FRG.
authors.forename: T H
authors.initials: TH
authors.lastname: Ittel
authors.forename: U
authors.initials: U
authors.lastname: Gladziwa
authors.forename: W
authors.initials: W
authors.lastname: Mück
authors.forename: H G
authors.initials: HG
authors.lastname: Sieberth
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000535:Aluminum / Q000097:blood*; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000493:pharmacokinetics; D000863:Antacids / Q000009:adverse effects* / Q000493:pharmacokinetics; D003422:Critical Care; D005260:Female; D006801:Humans; D007408:Intestinal Absorption; D007674:Kidney Diseases / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood; D008276:Magnesium Hydroxide / Q000009:adverse effects / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged
chemical_list: D000863:Antacids; D000536:Aluminum Hydroxide; C016545:magaldrate; D000535:Aluminum; D008276:Magnesium Hydroxide